|
BioPharma Deals 2026 to
focus on licensing, M&A and
strategic partnerships
(MUNICH)
-
The
biopharmaceutical industry
is facing a changing
dealmaking environment as
companies reassess their
pipelines, seek external
innovation and explore new
approaches to financing and
strategic growth. These
developments will form part
of the agenda at
BioPharma Deals 2026,
scheduled to take place on
24–25 November in Munich,
Germany.
The
conference is expected to
bring together professionals
working across business
development, licensing,
corporate development,
investment, mergers and
acquisitions (M&A), and
strategic partnerships.
Discussions will examine
commercial and investment
opportunities across the
biotechnology and
pharmaceutical sectors,
alongside the factors
influencing deal activity.
Topics on the agenda
include licensing and
partnering, M&A,
co-development agreements,
investment, due diligence,
asset valuation, and
strategic transactions.
Sessions will address
current market conditions
and the considerations
shaping negotiations and
collaboration between
biopharmaceutical companies.
A structured one-to-one
partnering program is also
planned, with more than 500
meetings expected during the
two-day event. The program
is intended to connect
organizations exploring
potential transactions,
including emerging
biotechnology companies
seeking development or
commercialization partners
and pharmaceutical companies
assessing external assets
and technologies.
Attendees are expected to
include representatives from
pharmaceutical and
biotechnology companies,
investment firms, advisory
organizations, and other
participants in the life
sciences transaction market.
Strategic
priorities shape biopharma
deal activity
The current market
environment is placing
greater emphasis on
selectivity and strategic
alignment in
biopharmaceutical
dealmaking. Companies are
increasingly assessing
external opportunities
against pipeline priorities,
commercial objectives,
development capabilities,
and longer-term portfolio
strategies.
For
biotechnology companies
seeking partners or
investment, scientific
potential remains important,
but it is only one part of
the assessment. Development
plans, clinical data,
differentiation, commercial
prospects, and funding
requirements can all
influence the attractiveness
of an asset or company to
potential partners.
For pharmaceutical
companies, external
innovation continues to
provide a route to accessing
new technologies,
therapeutic candidates, and
development capabilities.
However, decisions around
licensing and acquisitions
also require consideration
of portfolio fit,
development risk,
competitive positioning, and
the potential commercial
value of an opportunity.
These pressures are
contributing to a broader
role for business
development teams. In
addition to identifying and
negotiating individual
transactions, these
professionals are
increasingly involved in
portfolio planning, market
intelligence, competitive
analysis, and the
development of longer-term
relationships with potential
partners.
Against
this backdrop, BioPharma
Deals 2026 will address the
commercial and strategic
considerations influencing
transactions across the
biopharmaceutical sector.
The conference will take
place in Munich on 24–25
November 2026.
Further information about
the conference program,
speakers and registration is
available at:
https://www.biopharmadeals.com/
PRINT
THIS ARTICLE
|